This activity was produced prior to the accelerated FDA approval of mosunetuzumab for the treatment of adult patients with relapsed or refractory follicular lymphoma following treatment with at least 2 prior lines of systemic therapy.

Community Practice Considerations: Emerging Bispecific Antibodies in NHL


P. Connor Johnson, MD
Instructor of Medicine, Harvard Medical School
Center for Lymphoma
Massachusetts General Hospital
Boston, MA

RELEASED DATE: December 21, 2022
EXPIRATION DATE: December 21, 2023

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Scroll to Top